Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Am J Ophthalmol. 2023 Jan 21;251:12–23. doi: 10.1016/j.ajo.2023.01.019

TABLE 2.

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): Baseline Medical and Ocular History and Falls Risk

Variable Total Participants (n = 708) Intervention Group (n = 454) Usual Care Group (n = 254) P Value

Medical Conditions (Self-Reported), n (%)
Hypertension 444 (62.7) 286 (63.0) 158 (62.2) .835
Diabetes 206 (29.1) 130 (28.6) 76 (29.9) .718
Arthritis/osteoporosis 327 (46.2) 220 (48.5) 107 (42.1) .105
Foot problems 251 (35.5) 167 (36.8) 84 (33.1) .322
Heart problems 139 (19.6) 87 (19.2) 52 (20.5) .674
Depression 125 (177) 81 (178) 44 (17.3) .862
Asthma/COPD 118 (16.7) 88 (19.4) 30 (11.8) .010a
Cancer 47 (6.6) 31 (6.8) 16 (6.3) .786
Other medical conditions 80 (11.3) 51 (11.2) 29 (11.4) .941
No medical conditions 80 (11.3) 53 (11.7) 27 (10.6) .674
Current Smoker, n (%) 103 (14.5) 70 (15.4) 33 (13.0) .380
COVID-19 Vaccination Status (Self-Reported), n (%)
Vaccinated (at least 2 shots) 565 (79.8) 345 (76.0) 220 (86.6) .001a
Not vaccinated for COVID-19 123 (17.4) 98 (21.6) 25 (9.8) .000a
Ocular Conditions (Self-Reported), n (%)
Dry eye 331 (46.8) 221 (48.7) 110 (43.3) .169
Blurry vision 272 (38.4) 185 (40.7) 87 (34.3) .088
Cataract 199 (28.1) 122 (26.9) 77 (30.3) .328
Glaucoma 83 (11.7) 55 (12.1) 28 (11.0) .665
Floaters 111 (15.7) 60 (13.2) 51 (20.1) .016a
Double vision 51 (7.2) 38 (8.4) 13 (5.1) .108
Diabetic retinopathy 13 (1.8) 10 (2.2) 3 (1.2) .332
Macular degeneration 8 (1.1) 7 (1.5) 1 (0.4) .166
No ocular conditions 154 (21.8) 95 (20.9) 59 (23.2) .476
Family History (Self-Reported), n (%)
Family history of glaucoma 168 (23.7) 100 (22.0) 68 (26.8) .155
Family history of blindness 72 (10.2) 44 (9.7) 28 (11.0) .574
Wears Prescription Eyeglasses, n (%) 504 (71.2) 331 (72.9) 173 (68.1) .176
Age of Eyeglasses, n (%)
<1 y 101 (20.0) 66 (19.9) 35 (20.2) .938
1–2 y 123 (24.4) 80 (24.2) 43 (24.9) .865
>2 y 238 (47.2) 158 (477) 80 (46.2) .750
Can’t remember 42 (8.3) 27 (8.2) 15 (8.7) .843
Last Dilated Eye Examination, n (%)
Within the past year 167 (23.6) 107 (23.6) 60 (23.6) .987
Within 1–2 y 163 (23.0) 107 (23.6) 56 (22.0) .645
>2 y 250 (35.3) 162 (35.7) 88 (34.6) .782
Can’t remember 82 (11.6) 47 (10.4) 35 (13.8) .172
Never had eye examination 46 (6.5) 31 (6.8) 15 (5.9) .633
Reason for No Eye Examination in Past 2 y, n (%)
No reason to go 108 (28.9) 76 (32.1) 32 (23.4) .073
Not thought about it 59 (15.8) 42 (177) 17 (12.4) .174
No vision insurance 25 (6.7) 16 (6.8) 9 (6.6) .946
Cost of eye examination 10 (2.7) 6 (2.5) 4 (2.9) .823
Don’t have an eye doctor 16 (4.3) 11 (4.6) 5 (3.6) .648
Couldn’t get appointment 11 (2.9) 5 (2.1) 6 (4.4) .211
No transportation to office 4 (1.1) 2 (0.8) 2 (1.5) .577
Other, including COVID 141 (37.7) 79 (33.3) 62 (45.3) .022a
NEI-VFQ-8 Mean Composite Score ± SD 68.3 ± 11.6 673 ± 11.5 70.0 ± 11.8 .003a
Falls History, n (%) (Pre-screening)
Worries about falling and feels unsteady when standing or walking 296 (41.8) 177 (39.0) 119 (46.9) .042a
Fell in the past year 1–5 times 176 (24.9) 108 (23.8) 68 (26.8) .378
Visited emergency room due to falling 59 (8.3) 32 (7.0) 27 (10.6) .098
Hospitalized due to falling 23 (3.2) 12 (2.6) 11 (4.3) .224
Conduct STEADI in the Field 351 (49.6) 210 (46.3) 141 (55.5) .018a

COPD = chronic obstructive pulmonary disease; NEI-VFQ-9 = National Eye Institute Vision Function Questionnaire–9; NYC-SIGHT = New York City–Screening and Intervention for Glaucoma and Eye Health Through Telemedicine; STEADI = Stopping Elderly Accidents, Deaths, and Injuries.

a

Statistically significant at P < .05 level.